Matthew Kapusta Sells 28,716 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 28,716 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $50.02, for a total value of $1,436,374.32. Following the transaction, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at approximately $25,971,734.54. The trade was a 5.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

NASDAQ:QURE opened at $47.51 on Friday. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -13.65 and a beta of 0.98. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The stock’s 50 day simple moving average is $27.84 and its two-hundred day simple moving average is $23.02. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. As a group, equities analysts anticipate that uniQure N.V. will post -3.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on QURE shares. Royal Bank Of Canada lifted their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. The Goldman Sachs Group increased their price target on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Leerink Partners boosted their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, TD Cowen restated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $61.67.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Torren Management LLC bought a new stake in shares of uniQure in the 4th quarter worth about $28,000. IFP Advisors Inc bought a new position in uniQure during the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure in the 4th quarter worth about $48,000. CIBC Private Wealth Group LLC purchased a new stake in uniQure in the 3rd quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 906 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.